Europe Bioreactors Market size surpassed USD 2.9 billion in 2021 and is expected to expand at 13.5% CAGR between 2022 and 2028. Rising prevalence of chronic diseases and increasing lifestyle related disorders like cancer and diabetes have influenced product innovation in the region. Advanced biotechnology solutions and upgradation of the pre-existing facilities will develop the market size.
Get more details on this report - Request Free Sample PDF
Biopharmaceuticals use these devices widely across research and for the development of vaccines or other therapeutic products. Bioreactors production in the region is set to grow as investments and funding by the governments are on the rise. The European Union provides finance to businesses for the development of innovative vaccines. For instance, it provided USD 478 million for the COVID-19 vaccine program, which was led by the World Health Organization (WHO).
Europe Market, By Product Type
The Europe bioreactors market from single-use segment will exceed USD 2 billion revenue by 2028. In biomanufacturing facilities, single-use bioreactors are widely employed as they provide multiple benefits to the makers. It allows flexibility in using the same floor space to create numerous low-volume product types while producing a large quantity of several items, and a decrease in cross-contamination. The upcoming years will witness faster uptake of these components, attributed to the increased emphasis on research & development.
Europe Market, By Cell
The bacterial cells segment will observe around 13% growth during the forecast timeframe. Utilizing bacterial cells facilitates high-density culture by enhancing oxygen and nutrient supply as well as temperature control. Many large biopharma manufacturing companies are utilizing microbial cells to produce a range of goods. Personalized medicine usage is steadily increasing as, fueling the demand for bacterial cell bioreactors. Targeted therapy allows personalized medicine to treat several diseases like rheumatoid arthritis, cancer, and other autoimmune diseases.
Europe Market, By Country
Germany bioreactors market will witness lucrative growth rate through 2028, owing to the presence of major companies in the country. Leading solution providers in the country have a favorable effect on the supply and availability of goods. Germany being one of the largest exporters of medicinal products, is predicted to witness consistent surge in biopharma production. With the global need for personalized medicine and monoclonal antibodies, the country has become one of the main suppliers of novel biopharmaceuticals.
Competitive Industry Landscape
Key players operating in the Europe bioreactors market include Applikon Biotechnology, Inc. (Getinge), Sartorius Stedim Biotech, Eppendorf AG, Pierre Guerin Sas, Merck Group, Solaris Biotech Solutions, Danaher Corporation (Cytiva), Solida Biotech, and Cellexus Limited. The companies are implementing a variety of methods, including partnerships and the launch of new products, to strengthen their position in the industry.